X

Trial Profile

MJR-35 phase 2 study to investigate the efficacy and safety in patients with functional dysmenorrhea

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dienogest (Primary) ; Drospirenone/ethinylestradiol
Indications Dysmenorrhoea
Focus Adverse reactions; Therapeutic Use
Sponsors Mochida Pharmaceutical

Most Recent Events

11 Nov 2019 Primary endpoint (Change from baseline in the dysmenorrhea score at week 12 of treatment) has been met according to Results published in the Fertility and Sterility
11 Nov 2019 Results published in the Fertility and Sterility
16 Dec 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com